We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

ReNeuron Receives US Patent on Cell Cryopreservation Technology

ReNeuron Receives US Patent on Cell Cryopreservation Technology

ReNeuron Receives US Patent on Cell Cryopreservation Technology

ReNeuron Receives US Patent on Cell Cryopreservation Technology

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ReNeuron Receives US Patent on Cell Cryopreservation Technology "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The patent application, “Cellular Compositions for use in Therapy” (No. 13/132,475), contains broad claims relating to cryopreserved neural, retinal and mesenchymal stem cells using a formulation developed by ReNeuron researchers that, uniquely, is free of toxic cryopreservants. 

ReNeuron has deployed its cryopreservation technology to its lead CTX stem cell line to derive a cryopreserved, long shelf life cell therapy candidate, designated CTXcryo. The Company has received regulatory approval to use CTXcryo, with a current six-month shelf life, in its ongoing UK clinical trials in both stroke disability and critical limb ischaemia. 

ReNeuron believes that its patented CTXcryo product will provide the Company with significant commercial and competitive advantages in terms of the availability of a genuine off-the-shelf, low cost-of-goods cell therapy candidate with a shelf life enabling shipping to, and storage at, clinical sites on a global basis. 

Equivalent patents to the allowed US patent have already issued in Europe, Japan and Australia. 

ReNeuron has broad and multi-layered patent protection covering all of its cellbased technologies and therapeutic candidates. The Company owns or has exclusively licensed more than 80 issued patents, providing protection for its technologies in key potential markets across the globe. 

Olav Hellebø, Chief Executive Officer of ReNeuron, said: “The US Notice of Allowance for our cell cryopreservation technology is an important further addition to ReNeuron’s extensive patent estate. We have invested heavily in patents over the years, an investment that we believe will provide significant returns for the Company as our technologies and therapeutic candidates approach commercialisation.”